{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-204195","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.953537+00:00","generated_at":"2026-06-24T07:29:18.898289+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Karyopharm EVP Chief Development Officer Ran Frenkel to depart Aug 15; Stuart Poulton promoted to succeed","bullets":["Ran Frenkel to cease as EVP, Chief Development Officer effective August 15, 2022.","Stuart Poulton promoted to EVP, Chief Development Officer effective July 27, 2022.","Poulton previously SVP, Strategy and Portfolio Management since Feb 2022; 25+ years at AbbVie, Amgen, Eli Lilly.","Data sciences, clinical pharmacology, data management, medical writing, quality consolidated under Poulton or CMO Reshma Rangwala.","Company plans separation and consulting agreements with Frenkel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-204195","json":"https://secwatch.observer/filing/0001193125-22-204195.json","markdown":"https://secwatch.observer/filing/0001193125-22-204195.md","text":"https://secwatch.observer/filing/0001193125-22-204195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/d324083d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:29:18.898289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fdc51c40d","claim":"Stuart Poulton changed role as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..","evidence_excerpt":"Stuart Poulton, who has served as the Company’s Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Executive Vice President, Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"8a649d985d","claim":"Ran Frenkel departed as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..","evidence_excerpt":"On July 26, 2022, Karyopharm Therapeutics Inc. (the “Company”) and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company’s Executive Vice President, Chief Development Officer effective August 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease to serve"},{"label":"Role","value":"Executive Vice President, Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}